Is Royalty Pharma Plc (RPRX) overvalued? · P/E 15, rev $1.30B
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
This page asks whether Royalty Pharma Plc (RPRX) looks expensive on cached numbers — not a short thesis.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
RPRX currently screens at market cap $20.45B and trailing P/E 14.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RPRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RPRX stock page for the full model, not this heading.
Not investment advice.